Endorphin Benefits: What Studies Report

What "endorphin" refers to in the published literature

Endorphins are endogenous opioid peptides produced inside the body, best known through beta-endorphin, a fragment of pro-opiomelanocortin that binds opioid receptors. That distinction matters for anyone reading about "endorphin benefits": the large majority of indexed research does not administer endorphin to people and measure what happens. Instead, it either measures endogenous opioid peptides as an outcome alongside something else, or proposes endorphin release as a mechanism that might explain an observed effect. A 2009 review of peripheral mechanisms of opioid analgesia described how opioid peptides released from immune cells within inflamed tissue can activate peripheral opioid receptors and produce analgesia outside the central nervous system (PMID 19157985). For background on the molecule itself, see the overview page on Endorphin.

How the evidence on this page is labelled

Study design determines how much weight a finding can carry. Systematic reviews and randomised controlled trials in humans sit at one end; narrative reviews, mechanistic discussions and animal experiments sit at the other. Throughout this page, each claim names the study type, the population where one was reported, and the direction of effect the authors described. Where a mechanism is proposed rather than measured, it is labelled as such. Where the verified literature does not address a commonly repeated claim, that gap is stated plainly rather than filled with inference.

Pain and analgesia: the most studied domain

Peripheral opioid analgesia

The clearest mechanistic literature concerns opioid receptors outside the brain. The 2009 review in Current Opinion in Pharmacology summarised evidence that opioid peptides derived from immune cells act at peripheral opioid receptors on sensory neurons, a pathway the authors framed as a route to analgesia with potentially fewer central effects (PMID 19157985). That review was a synthesis of mechanistic and preclinical work rather than a trial of an endorphin product in patients.

Acupuncture and pain management

A 2016 review in Current Pain and Headache Reports examined the role of acupuncture in pain management and discussed endogenous opioid signalling among the mechanisms proposed to explain acupuncture analgesia (PMID 26896946). As a narrative review, it described the state of the field rather than generating new effect estimates, and the endorphin mechanism it discussed remained a proposed explanation rather than a measured outcome in patients.

Labour pain and birth satisfaction

One randomised controlled trial sits in this cluster. Researchers reported in Explore in 2024 on acupressure and massage applied during labour, with labour pain and birth satisfaction as the measured outcomes, and described differences favouring the intervention conditions (PMID 38693027). The study measured pain and satisfaction scores; it was not designed as an assay of circulating endorphin concentrations, so any endorphin explanation remains interpretive.

Procedural pain in preterm infants

A 2025 review in Frontiers in Pediatrics examined multisensory stimulation therapy for pain during retinopathy of prematurity screening, a setting where non-pharmacological comfort measures are used during a painful eye examination (PMID 40909429). Endogenous opioid release is among the mechanisms commonly proposed for such interventions, but the review was a synthesis of research progress in a neonatal population rather than a measurement of endorphin levels.

Migraine during pregnancy

A 2024 review in Cureus covered abortive and prophylactic therapies for migraine in pregnancy, a population in which medication options are constrained (PMID 39493026). The review surveyed treatment options and their reported evidence base; it did not report endorphin administration or endorphin measurement as a therapy.

A newer mechanistic thread: GLP-1 receptor agonists

A 2025 review in The Journal of Headache and Pain examined GLP-1 receptor agonists for pain treatment and their future potential, discussing — largely on the basis of preclinical and animal work — signalling pathways through which GLP-1 receptor activation has been linked to endogenous opioid peptide release and antinociception (PMID 40016636). This is mechanistic and animal-level evidence as described in that review, not a demonstration of clinical benefit in human pain populations.

Social bonding and human–animal interaction

One frequently cited human study measured hormone changes around social contact. The 2003 report in The Veterinary Journal examined neurophysiological correlates of affiliative behaviour between humans and dogs and reported changes in several plasma hormone concentrations, including beta-endorphin, in both species after a period of positive interaction (PMID 12672376). The study was small and observational in design, measured short-term hormonal correlates rather than clinical endpoints, and did not test whether those hormonal shifts caused any change in mood or health.

Sleep

Endorphin release is sometimes offered as an explanation for sleep effects attributed to acupuncture. A 2013 review in International Review of Neurobiology examined acupuncture for the treatment of insomnia and characterised the clinical trial literature as limited by heterogeneity and methodological quality (PMID 24215925). That review did not report endorphin concentrations as a trial outcome, so sleep claims that invoke endorphins rest on mechanism rather than on measured peptide data.

Reproductive and metabolic outcomes: polycystic ovary syndrome

Three papers in the verified set address acupuncture in polycystic ovary syndrome, an area where endogenous opioid signalling has been proposed as part of the rationale. The 2011 Cochrane review of acupuncture for polycystic ovarian syndrome reported that the available trials were insufficient to determine effectiveness (PMID 21833961), and the 2016 update of that Cochrane review again reported insufficient evidence on which to base conclusions about clinical outcomes (PMID 27136291). A 2019 review in Current Opinion in Obstetrics & Gynecology examined the efficacy of acupuncture in managing polycystic ovarian syndrome and discussed the trial evidence and its limitations (PMID 31567447). Taken together, the Cochrane assessments did not establish benefit (PMID 27136291).

Movement disorders

A Cochrane review published in 2000 examined miscellaneous treatments for neuroleptic-induced tardive dyskinesia, a category that has historically included a wide assortment of agents tested in small trials, and reported that the evidence was too limited to support the use of those interventions in routine care (PMID 10796325). This is an example of an area where an endogenous-opioid rationale has been explored historically without the trial base to support conclusions.

Summary of domains and what was reported

Claims this literature does not establish

Several widely repeated ideas are not supported by the papers cited here, and saying so is more useful than filling the gap. The verified set contains no trial of an administered endorphin product in humans, and therefore no dose, no treatment duration and no outcome data for such a product. It contains no study of exercise-induced euphoria or "runner's high", no trial of endorphins for depression, anxiety or general mood, no study of endorphins and body weight or appetite in humans, and no study of oral endorphin supplementation — oral peptides of this kind would in any case face digestive breakdown, a point no paper in this set tested. Where endorphin release appears, it appears as a proposed explanation for an effect attributed to something else, such as acupuncture analgesia (PMID 26896946) or peripheral opioid receptor activation in inflamed tissue (PMID 19157985).

Adverse Events: What Studies Report

Because the verified papers do not administer endorphin as a drug, none of them reports an adverse-event profile for such an intervention. What they report instead is uncertainty about the interventions they did examine: the 2016 Cochrane review of acupuncture for polycystic ovarian syndrome reported that the evidence base was insufficient for firm conclusions, which limits what can be said about harms as well as benefits (PMID 27136291), and the Cochrane review of miscellaneous treatments for neuroleptic-induced tardive dyskinesia reported that the trials were too small and too few to guide practice (PMID 10796325). Mechanistic reviews such as the 2009 synthesis of peripheral opioid analgesia discussed the theoretical appeal of restricting opioid action to the periphery, which implies that central opioid effects remain a safety consideration whenever opioid receptor pathways are engaged (PMID 19157985).

What remains unanswered

• Whether measurable changes in circulating beta-endorphin, such as those reported after human–dog interaction, translate into any clinical outcome (PMID 12672376).
• Whether endorphin release is the operative mechanism behind the pain and satisfaction differences reported in the 2024 acupressure and massage trial, which did not measure peptide concentrations (PMID 38693027).
• Whether the GLP-1 receptor pathways linked to endogenous opioid release in preclinical work carry over to human pain conditions (PMID 40016636).
• Whether larger, better-designed trials would change the insufficient-evidence conclusions reported for acupuncture in polycystic ovary syndrome (PMID 31567447).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, symptom or treatment decision. It summarises what published studies measured and reported, and nothing here describes a regimen, an outcome anyone should expect, or a reason to use any substance.

References

• Advances in GLP-1 receptor agonists for pain treatment and their future potential (The Journal of Headache and Pain, 2025)
• Neurophysiological correlates of affiliative behaviour between humans and dogs (Veterinary Journal, 2003)
• Peripheral mechanisms of opioid analgesia (Current Opinion in Pharmacology, 2009)
• Acupuncture for polycystic ovarian syndrome (The Cochrane Database of Systematic Reviews, 2016)
• The effect of acupressure and massage on labor pain and birth satisfaction: a randomized controlled trial (Explore, 2024)
• The Role of Acupuncture in Pain Management (Current Pain and Headache Reports, 2016)
• The efficacy of using acupuncture in managing polycystic ovarian syndrome (Current Opinion in Obstetrics & Gynecology, 2019)
• Acupuncture for polycystic ovarian syndrome (The Cochrane Database of Systematic Reviews, 2011)
• Research progress on multisensory stimulation therapy for pain during retinopathy of prematurity screening (Frontiers in Pediatrics, 2025)
• Abortive and Prophylactic Therapies to Treat Migraine in Pregnancy: A Review (Cureus, 2024)
• Miscellaneous treatments for neuroleptic-induced tardive dyskinesia (The Cochrane Database of Systematic Reviews, 2000)
• Acupuncture for the treatment of insomnia (International Review of Neurobiology, 2013)